the bottom line is this: ENTs aren't bought into the product, if they were they would use it particularly in cases where it is reimbursed. The company wouldn't have made it at a $100/vial. Docs always complain about price and access when the truth is they really just don't want to use the product. You have to ask yourself why you came to work for otonomy and sell otiprio in the first place? Did you believe in the product? If so, go sell it. If not, then leave and then you can stop complaining. Furthermore, the way the IC is set up you don't have to sell drug so why are you complaining anyway, you are going to make ur bonus.
Show us just one paid claim genius. ENT's or their staff are not going to cherry pick patients based on insurance, and we have zero proof of one covered case from any payer 6 months post launch meeting. Even if they did, is that going to provide any legitimate revenue stream? If you think ENT's, Hospitals, or ASC's are just going to eat the cost and that is the strategy, you are dumber than we think you are. Trust us, we didn't think that was possible, because everybody involved in pre-planning this launch should be working at Burger King.
Dumb shit like the conference call Friday is exactly why this place is a joke. Think of the family, think of compliance, think of expanding beyond specialized use. No shit. Fucking 101 Why don't you idiots think of a new pricing and reimbursement strategy. Million dollar hub. Another wise move. NOT
Focus on your administrative bs so you look good on all the reports. Does anyone care about making $?
As long as you have that dumbfuck Dino Lunch as VP in managed markets you might as well get used to the same BS in reimbursement and pricing as you've been getting all along. Look what that vacuum did for Cubist, Optimer and Roche.
Funny, you take managers from other companies that could not sell like DM and then you expect a different result. Fish stinks from the head!!!! Or from Mr. Weazy himself, MS.
As long as you have that dumbfuck Dino Lunch as VP in managed markets you might as well get used to the same BS in reimbursement and pricing as you've been getting all along. Look what that vacuum did for Cubist, Optimer and Roche.
